|
Dendreon Corporation, based in Seattle, Washington, is a biotechnology firm that develops cancer immunotherapies. The company's sipuleucel-T active cellular immunotherapy candidate, in clinical trials, treats prostate cancer. The firm also is developing compounds that target the Trp-p8 protein, which is expressed on the surface of multiple cancer cell types. Trp-p8 therapies are developed in collaboration with Genentech Incorporated, Abgenix Incorporated, and Dyax Corporation. Dendreon also is developing active immunotherapies, monoclonal antibodies, and small molecules that can be used in treating ovarian, colorectal, breast, kidney, and cervical cancers. The firm's proprietary Antigen Delivery Cassette (TM) technology supports the destruction of cells that express targeted proteins. Dendreon is listed on NASDAQ under the DNDN symbol.
|
Information Sources, Inc.